21results about "Libraries" patented technology

Compositions and methods are provided that include binding partners that specifically bind to peptide conjugate / MHC complexes, including peptide conjugates formed by covalent reaction of a targeted covalent inhibitor with a peptide. The binding partners are provided as antibodies and antibody derivatives that specifically bind to the peptide conjugate / MHC complex.

Compositions, methods, and systems for selecting polynucleotides for their activity as neuron-specific transcription factors are disclosed herein. [Solution] The system of the present invention may include a library of polynucleotides encoding reporter proteins and panneuronal markers, Gas proteins, and guide RNAs (gRNAs) that target putative transcription factors. A method for screening neuron-specific transcription factors is further provided.

The presently disclosed subject matter relates to multispecific antibodies, e.g., bispecific antibodies and biepitopic antibodies, and methods for screening for such antibodies, and a novel antibody structure that can be used to screen for such bispecific antibodies and biepitopic antibodies. The present disclosure further provides bispecific anti-KLB antibodies and methods for treating diseases using these antibodies.

Compositions of peptides modified to enhance HLA binding or T cell recognition while preserving reactivity to target neoepitopes enhance the activation of neoantigen-specific T cells. The method of use involves treating cancer by administering one or more of these peptides, which are produced by computer modeling.

The presently disclosed subject matter relates to multispecific antibodies, e.g., bispecific antibodies and biepitopic antibodies, and methods for screening for such antibodies, and a novel antibody structure that can be used to screen for such bispecific antibodies and biepitopic antibodies. The present disclosure further provides bispecific anti-KLB antibodies and methods for treating diseases using these antibodies.

The disclosure relates to compositions and systems comprising nucleic acid sequences that encode and amino acid sequences that comprise a first, second, and third region, each region forming a confirmational trimer and scaffold to associate with and identify certain epitopes against which Immunotherapeutics may bind. Methods of using the polypeptide sequences are also disclosed.

Compositions and methods are provided for enhancing homologous recombination repair in gene editing applications using improved inhibitors of 53BP1. The present disclosure provides compositions and methods for enhancing HDR-mediated integration of polynucleotides in gene editing applications. The methods utilize polypeptide compositions that bind to p53 binding protein 1 (53BP1) and inhibit 53BP1 promotion of the NHEJ DNA repair pathway, favoring HDR-mediated DNA repair.

We provide a therapeutic drug delivery polypeptide that can be used for treatment. [Solution] The present invention relates to a protein suitable for use as a scaffold to which a target peptide binds, or a protein contained within a complex to which a target agent binds. It also relates to a complex suitable for selectively delivering a complex of a target agent to specific types of cells and tissues. It also relates to nanoparticles containing such a complex. In one embodiment, a polypeptide is provided comprising (i) 11 β-chain domains designated A, B, C, D, E, F, G, H, I, J, and K, and (ii) 10 loop regions connecting two consecutive β-chain domains, designated AB, BC, CD, DE, EF, FG, GH, HI, IJ, and JK loops, wherein at least one of the loop regions is a homogeneous loop region variant, and at least one of the β-chain domains is a homogeneous β-chain variant.

Methods and compositions are provided for obtaining functionally enhanced induced effector cells obtained from directed differentiation of genomically engineered iPSCs. The iPSC-derived cells provided herein have stable, functional genome editing that results in improved or enhanced therapeutic effects. Therapeutic compositions and uses thereof are also provided, comprising the functionally enhanced induced effector cells alone or in combination with antibodies or checkpoint inhibitors in combination therapy.

The present invention provides an infectious recombinant adeno-associated virus (rAAV) virion containing heterologous nucleic acid that has improved resistance to human AAV neutralizing antibodies. The present invention also provides a method for delivering heterologous nucleic acid-containing rAAV virions to target cells. [Solution] An infectious recombinant adeno-associated virus virion comprising (a) a mutant adeno-associated virus capsid protein comprising an amino acid sequence having at least about 90% amino acid sequence identity to a specific amino acid sequence, and (b) a heterologous nucleic acid.

Antigen binding proteins that bind to HLA-PEPTIDE and HLA-PEPTOID targets are provided. Methods of identifying HLA-PEPTIDE targets are also provided, as well as methods of identifying one or more antigen binding proteins that bind to a given HLA-PEPTIDE target.SOLUTION: An isolated antigen binding protein (ABP) that specifically binds to a human leukocyte antigen (HLA)-PEPTIDE target is provided, wherein the HLA-PEPTIDE target may comprise a particular HLA restriction peptide having a defined amino acid sequence complexed with a particular HLA subtype.SELECTED DRAWING: Figure 2

The present invention relates to a prolactin receptor antibody and its applications, and more specifically to an antibody or its antigen-binding fragment that targets PRLR, or a variant that retains its PRLR-binding activity while having at least 85% sequence identity with the antibody or its antigen-binding fragment, wherein the antibody targets an extracellular segment that targets the prolactin receptor. The antibody of the present invention binds to PRLR with high affinity.

The invention relates to C. acnes carrying DNA vectors with a C. acnes phage packaging signal and a gene of interest. The invention encompasses a C. acnes producer cell carrying DNA vectors, with a C. acnes phage packaging signal and a gene of interest, for the production of phage-derived particles that can robustly transduce C. acnes receiver cell allowing transgene expression. The invention encompasses C. acnes phage-derived particles carrying these vectors, C. acnes containing these vectors or modified by transduction of these phage-derived particles, and methods of using these phage-derived particles.

Disclosed herein are systems and methods for screening chimeric libraries for binding to a target of interest. Also disclosed herein are high throughput methods for identifying candidate chimeric biologics having improved biological activity against a target of interest.

Cellular vaccine platforms, such as vaccine immunity virus opsonization platforms, for eliciting a host immune response are disclosed. Methods of making and using the cellular vaccine platforms for stimulating a host immune response are also disclosed. Some embodiments provide genetically engineered human cells comprising: (a) a genomic disruption in at least one human leukocyte antigen (HLA) gene or at least one transcriptional regulator of an HLA gene; and (b) an exogenous nucleic acid encoding a cell surface protein, or a functional fragment or variant of the cell surface protein, that binds to a protein expressed on the surface of a phagocytic or cytolytic immune cell, wherein said binding results in activation of the phagocytic or cytolytic activity of the immune cell.

The present invention relates to proteins suitable for use as scaffolds to which peptides of interest are attached, or proteins contained within complexes to which agents of interest are attached. The present invention also relates to complexes suitable for selectively delivering complexes of agents of interest to specific cell and tissue types, where the agents may be therapeutic or imaging agents. The present invention also relates to nanoparticles comprising such complexes and their therapeutic uses.

Compositions, methods and systems for targeted delivery using one or more shuttles operably linked to one or more cargos (e.g., cargo polypeptides, e.g., cargo oligonucleotides) and subsequent quantification of an abundance of one or more cargos (e.g., proteins) in a mixture (e.g., a complex mixture (e.g., in vivo)) or in a specific cell, tissue, or organ of interest (e.g., in vivo) using barcodes (e.g., peptide barcodes), binders (e.g., polypeptide binders), and binding agents (e.g., phage) are provided herein.

Provided herein are methods and compositions relating to polyomavirus epitopes that are useful for treating cancer or polyomavirus infection.

The present invention provides a covalently surface modified adeno-associated virus, which can comprise a covalently surface modified adeno-associated virus that can comprise a gene of interest; gOI) and can advantageously target certain cell and tissue types for prophylactic and therapeutic purposes. The invention also provides systems and methods for engineering adeno-associated viruses (AAVs) to produce covalently surface modified adeno-associated viruses, as well as methods of purifying these covalently surface modified adeno-associated viruses. The invention also includes covalently surface modified adeno-associated viruses and formulations and products comprising these covalently surface modified adeno-associated viruses.

Methods for preparing individualized cancer vaccines and methods for training machine learning HLA peptide presentation prediction models.

Multispecific antibodies and methods of screening for such antibodies are provided.SOLUTION: The presently disclosed subject matter relates to multispecific antibodies, e.g., bispecific antibodies and biepitopic antibodies, and methods of screening for such antibodies, as well as novel antibody structures that can be used in screening for such bispecific antibodies and biepitopic antibodies. The present disclosure further provides bispecific anti-KLB antibodies and methods of treating diseases using these antibodies.SELECTED DRAWING: None